Core Viewpoint - Bloom Energy's stock price experienced a significant decline, dropping 16.5% at one point and closing down 10.6% after Jefferies downgraded the stock rating from "Hold" to "Underperform" with a target price of $31, citing unclear growth prospects post-2026 and early signs of excessive optimism [1] Group 1: Analyst Insights - Jefferies' analyst team, led by Dushyant Ailani, acknowledges Bloom Energy's leadership in promising segments but highlights that many optimistic growth assumptions are facing real-world constraints [1] - The current stock valuation corresponds to an expected EBITDA multiple of approximately 31 times for the fiscal year 2027, implying high growth expectations, while the downside risks appear to outweigh the potential for further increases [1] - Analysts express skepticism regarding the justification of a 30x valuation multiple given the unclear growth trajectory beyond 2027, noting that even a more reasonable valuation multiple seems difficult to achieve in terms of business scale [1] Group 2: Order and Growth Concerns - A major point of contention is the speed at which the company signs orders, with management previously stating that securing large orders takes time [1] - While Jefferies does not underestimate Bloom Energy's potential to achieve over 1 GW of business scale, they see little likelihood of reaching this goal in the short term [1] - The next potential catalyst for the stock will be on February 26, when Bloom Energy is expected to disclose its order backlog, but Jefferies remains doubtful about the stock's support level before this announcement [1]

Core Viewpoint - UBS reiterated a "Buy" rating for Elevance Health (ELV.US) with a target price of $435, indicating a potential upside of nearly 53% from the recent closing price of $283.48 [1] Financial Performance - Elevance Health reported Q2 revenue of $49.8 billion, exceeding market expectations [1] - Adjusted earnings per share (EPS) for Q2 were $8.84, in line with market expectations [1] - The company lowered its full-year EPS forecast by $4.50, equating to a pre-tax profit reduction of $1.3 billion [1] Future Projections - Elevance Health raised its 2025 medical loss ratio forecast by 90 basis points [1] - The increase in medical loss ratio expectations is attributed to unfavorable cost trends in the Affordable Care Act (ACA) transactions and Medicaid business [1] Investment Rationale - UBS maintains a "Buy" rating due to the potential profitability stability and growth opportunities in the commercial insurance and Carelon business segments, despite the raised medical loss ratio expectations [1]

Core Viewpoint - The Governor of the Bank of Japan, Kazuo Ueda, stated that the growth outlook remains fundamentally unchanged [1] Group 1 - The Bank of Japan's growth prospects have not seen significant alterations despite ongoing economic conditions [1]

Group 1 - The European Central Bank (ECB) President Christine Lagarde expects a weakening growth outlook in the near term [1] - The risks to the growth outlook remain skewed to the downside [1] - Inflation is projected to remain stable around 2% [1] - The ECB is in a favorable position to respond to uncertain times [1]